Related Experiment Video
Updated: Aug 31, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation
G R Stenton1, M K Kim, O Nohara
1Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Abstract:
Syk protein tyrosine kinase (PTK) is involved in signaling in leukocytes. In macrophages, Fcgamma-receptor cross-linking induces Syk PTK phosphorylation and activation, resulting in Syk-dependent events required for phagocytosis and mediator release. We hypothesized that Syk antisense oligodeoxynucleotides (ASO) delivered by aerosol to rat lungs in vivo would depress Syk PTK expression, mediator release from alveolar macrophages, and Syk-dependent pulmonary inflammation. RT-PCR and RT-in situ PCR demonstrated that aerosolized Syk ASO administration reduced Syk mRNA expression from alveolar macrophages compared with cells isolated from sham-treated rats. Western blot analysis confirmed that Syk PTK expression was reduced after Syk ASO treatment. Compared with sham-treated rats (scrambled oligodeoxynucleotide), Syk ASO treatment suppressed Fcgamma-receptor-mediated nitric oxide (86.0 +/- 8.3%) and TNF (73.1 +/- 3.1%) production by alveolar macrophages stimulated with IgG-anti-IgG complexes. In contrast, Fcgamma-receptor-induced IL-1beta release was unaffected by Syk ASO treatment. Additionally, Syk ASO suppressed Ag-induced pulmonary inflammation, suggesting that Syk ASO may prove useful as an anti-inflammatory therapy in disorders such as asthma.
Insights
Aerosolized Syk antisense oligodeoxynucleotides (ASO) reduced Syk protein tyrosine kinase (PTK) expression in rat lungs. Syk ASO treatment suppressed inflammatory mediator release and pulmonary inflammation, indicating potential asthma therapy.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Syk protein tyrosine kinase (PTK) is crucial for signaling in leukocytes, particularly in macrophages.
- Fcgamma-receptor activation in macrophages triggers Syk PTK phosphorylation and downstream events like phagocytosis and mediator release.
Purpose of the Study:
- To investigate the efficacy of aerosolized Syk antisense oligodeoxynucleotides (ASO) in reducing Syk PTK expression and Syk-dependent pulmonary inflammation in vivo.
- To assess the impact of Syk ASO on mediator release from alveolar macrophages.
Main Methods:
- Administration of Syk ASO via aerosol to rat lungs.
- Quantitative reverse transcription PCR (RT-PCR) and RT-in situ PCR to measure Syk mRNA expression.
- Western blot analysis to confirm Syk PTK protein expression levels.
- Stimulation of alveolar macrophages with IgG-anti-IgG complexes to assess mediator release (nitric oxide, TNF, IL-1beta).
- Evaluation of antigen-induced pulmonary inflammation.
Main Results:
- Aerosolized Syk ASO significantly reduced Syk mRNA and protein tyrosine kinase expression in rat alveolar macrophages.
- Syk ASO treatment suppressed Fcgamma-receptor-mediated nitric oxide and TNF production by alveolar macrophages.
- Fcgamma-receptor-induced IL-1beta release remained unaffected by Syk ASO treatment.
- Syk ASO administration effectively suppressed antigen-induced pulmonary inflammation.
Conclusions:
- Aerosolized Syk ASO is effective in reducing Syk PTK expression and associated inflammatory responses in the lungs.
- Syk ASO demonstrates potential as an anti-inflammatory therapeutic agent for respiratory disorders like asthma.
More Related Videos
06:29Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
10:21Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
Published on: September 20, 2024
Related Concept Videos
The JAK-STAT Signaling Pathway
Respiratory Syncytial Virus Disease
Inhibitors of Viral Protein Synthesis